Palantir jumps 17% on report of $44 million FDA contract
December 07, 2020 at 14:56 PM EST
The deal is worth $44.4 million and will focus on powering drug reviews and inspections, according to the report.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|